Skip to main
  1. Stocks
  2. Milestone Pharmaceuticals Inc
  3. Forecast
MIST

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals is attractive because CARDAMYST already has U.S. approval as the first self-administered PSVT rescue therapy, addressing a clear treatment gap by helping patients avoid emergency care and giving the company a differentiated commercial platform. The recent NMPA approval in China further validates etripamil’s clinical and regulatory profile, triggers a $2M milestone payment, and leaves up to $98M of additional milestones plus royalties of up to 18% on Greater China sales, all without requiring Milestone to build local infrastructure. With commercial coverage now above 50%, roughly 800 prescribers, an estimated 3M-6M diagnosed PSVT patients in China, and optionality from the larger AFib-RVR program, the stock offers multiple levers for non-dilutive growth and long-term upside.

Bears say

Milestone Pharmaceuticals is viewed negatively because Cardamyst’s launch has been weaker than expected, with soft early prescription volume, limited prescriber productivity, and sales that have not validated the broad PSVT opportunity. The company’s investment case has shifted from regulatory uncertainty to commercial execution risk, yet prescriber breadth remains shallow, EPs may over-index, and cardiologist adoption is still constrained by WPW education and patient self-treatment concerns. With management expecting weighted-average net revenue per Rx to remain well below $500 for the rest of 2026, the company still faces operating losses, reliance on a single product, and possible dilution if the launch fails to generate sufficient cash flow.

MIST has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

MIST Analyst Forecast & Price Prediction

Get the latest MIST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MIST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 5 analysts, MIST has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


MIST Analyst Forecast & Price Prediction

Get the latest MIST stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MIST

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MIST stock data and trends